Text Size

Validation of the Hebrew Version of the Montreal Affective Voices.

This study is not yet open for participant recruitment.
Verified January 2012 by Hadassah Medical Organization
Sponsor:
Information provided by (Responsible Party):
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT01512732
First received: January 15, 2012
Last updated: January 22, 2012
Last verified: January 2012
History of Changes
  Purpose

Today, no non-verbal auditory stimuli that assess mental processing are available in Israel. The goal of this study is to make available a validated set of auditory stimuli in Israel. We created a computerized Hebrew version of the Montreal Affective Voices (MAV). The MAV is a novel tool for assessing mental processing. The MAV consists of 90 nonverbal affect bursts corresponding to nine different emotions (such as anger, fear, happiness etc.) recorded by ten different actors. The uniqueness of these affective bursts is that they do not contain verbal context, but rather express affective moods using the vowel /a/ (as in "apple"). In this study, the investigators will verify the new Hebrew version of MAV in healthy control groups. Next, the investigators will compare the mental processing ability in young vs. old population, using the MAV test. In addition, the investigators will assess mental processing in two pathologic study groups (Parkinson's disease, major depressive disorder) using the MAV test. The investigators intend to use the MAV tool in future research in Parkinson's disease and depression.


Condition
Parkinson's Disease
Depression

Study Type: Observational

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • Verifying the results achieved by Belin et al (2008) when using the Hebrew version of the MAV bursts in healthy control groups. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Estimated Enrollment: 120
Study Start Date: February 2012
Groups/Cohorts
healthy control group
Young (20-49) and Older (50-70) healthy group (n=60)
Parkinson's disease patients
(n=30).
Major depressive disorder patients
(n=30).

  Eligibility

Ages Eligible for Study:   20 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

healthy group, Parkinson's disease patients, Major depressive disorder patients.

Criteria

Inclusion Criteria:

  • Healthy group
  • Parkinson's disease
  • Major depressive disorder
  • All participants will be competent and willing to give written informed consent. Patients over 65 and/or suspected to have a cognitive decline will be tested by the Mini-mental test and will be included in the study only if the score is above 26.

Exclusion Criteria:

  • Non-competent or unable to give written informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01512732

Contacts
Contact: Renana Eitan, Dr 972-050-4048165 renanaeitan@gmail.com

Locations
Israel
Hadassah Medical Organization, Not yet recruiting
Jerusalem,, Israel
Contact: Hadas Lemberg, PhD     00 972 2 6777572     lhadas@hadassah.org.il    
Principal Investigator: Renana Eitan, MD            
Sponsors and Collaborators
Hadassah Medical Organization
  More Information

No publications provided

Responsible Party: Hadassah Medical Organization
ClinicalTrials.gov Identifier: NCT01512732     History of Changes
Other Study ID Numbers: HebVerMAV-HMO-CTIL
Study First Received: January 15, 2012
Last Updated: January 22, 2012
Health Authority: Israel: Ministry of Health - Director General

Additional relevant MeSH terms:
Depression
Depressive Disorder
Parkinson Disease
Behavioral Symptoms
Mood Disorders
Mental Disorders
Parkinsonian Disorders
 Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases

ClinicalTrials.gov processed this record on June 18, 2013